Fibrinolytic agents, sometimes referred to as thrombolytic agents, are capable of dissolving blood clots that may block your veins or arteries. In general, cleaner arteries are a benefit to your cardiovascular health, which is one reason why fibrinolytic enzymes such as lumbrokinase, nattokinase, and serrapeptase should be on your radar.
In your body, enzymes regulate the rate of numerous biological reactions, speeding them up so necessary functions such as digestion, muscle contractions, and other aspects of cellular metabolism can occur.
Lumbrokinase, serrapeptase, and nattokinase are proteolytic enzymes that act as natural anticoagulants by breaking down fibrin that forms blood clots. Fibrin, a clotting material that restricts blood flow, is found both in your bloodstream and connective tissue such as your muscles. Fibrin accumulation is also responsible for scar tissue.
Fibrinolytic Enzymes Help Manage Heart Disease
Fibrinolytic enzymes are antihypertensive, anti-atherosclerotic, lipid-lowering, and anti-platelet agents, which also have neuroprotective effects. Much research into fibrinolytic enzymes has focused on nattokinase (NK), an active ingredient in natto, or fermented soybeans. It’s likely due to its high nattokinase content that natto consumption is linked to a decreased risk of heart disease mortality and increased longevity in the Japanese population.So, while all of the fibrinolytic enzymes are effective and beneficial, you’ll need much higher doses of nattokinase and, especially, serrapeptase, than lumbrokinase to achieve similar effects. If you are using a fibrinolytic enzyme, my strong personal preference and recommendation is to use lumbrokinase.
The study also found a significant reduction in carotid artery intima-media thickness. This is a measure of the extent of atherosclerotic vascular disease. The researchers noted improvement rates ranging from 66.5 percent to 95.4 percent. Those who smoked, drank alcohol, or had a higher BMI experienced the greatest lipid-lowering effects. No adverse effects were noted from the nattokinase.
It’s also interesting to note that regular exercise further improved nattokinase’s beneficial effects, and it also worked synergistically with consumption of vitamin K2 and aspirin. At a lower dose of 3,600 FU per day, nattokinase was ineffective at lowering lipids or suppressing the progression of atherosclerosis, highlighting the importance of proper dosing and “challenging the recommended dose of 2,000 FU per day,” the researchers explained.
“The available data suggest that the antiatherosclerotic effects of NK are due to the collective effects of the combination of the antithrombotic, anticoagulant, antioxidant and lipid-lowering properties of NK or the natto extract containing NK,” they wrote.
A Single Dose of Fibrinolytics Has Anticoagulant Benefits
A study published in Scientific Reports involving 12 men revealed that just one 2,000 FU dose of nattokinase enhanced fibrinolysis and anticoagulation. It activated multiple fibrinolytic and antithrombotic pathways simultaneously, the researchers wrote. At six and eight hours after the nattokinase was taken, D-dimer concentrations were significantly elevated.D-dimer is a protein fragment produced by the body when a blood clot dissolves. It’s typically undetectable or present only at very low levels, but its level may significantly rise when the body is forming and breaking down blood clots, as occurred after one dose of nattokinase in this study.
“Based on NK’s unique, comparatively strong fibrinolytic/anticoagulant activity, stability in the gastrointestinal tract and long bioavailability in vivo, NK would appear to offer potential advantages over other currently used agents for treatment and/or prevention of selected diseases processes,” the researchers added.
“NK might have an impact on not only fibrinolytic/anticoagulant pathways but also other risk factors for thrombosis.”
“The results indicate that nattokinase extracted from fermented soybean inhibit platelet aggregation by blocking thromboxane [a vasoconstrictor] formation, and thereby delay thrombosis following oxidative arterial wall injury. Therefore, it is suggested that nattokinase could be a good candidate without adverse effects for the improvement of blood flow,” the researchers wrote.
Fibrinolytic Enzymes for COVID-19
Fibrinolytic therapy may also be effective in treating COVID-19, as coagulopathy appears to play a role in severe COVID-19. Researchers noted this in a case series published in the Journal of Thrombosis and Haemostasis.“There is evidence in both animals and humans that fibrinolytic therapy in acute lung injury and acute respiratory distress syndrome (ARDS) improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS,” they wrote.
“This would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC [disseminated intravascular coagulation] on their laboratory values such as what is observed in more than 70 percent of those who die of COVID‐19.”
The researchers reported three case studies of patients with severe COVID‐19 respiratory failure who were treated with tissue plasminogen activator (TPA), a serine protease enzyme found on endothelial cells that’s involved in fibrinolysis, or the breakdown of blood clots. All three patients benefited from the treatment, with partial pressure of oxygen/FiO2 (P/F) ratios, a measure of lung function, improving from 38 percent to 100 percent.
In an interview with Reuters, study co-author Mauro Giacca, a professor at King’s College London, described “really vast destruction of the architecture of the lungs,” with healthy tissue “almost completely substituted by scar tissue,” which could be responsible for cases of “long COVID,” in which symptoms persist for months.
“It could very well be envisaged that one of the reasons why there are cases of long COVID is because there is vast destruction of lung (tissue),” he told Reuters. “Even if someone recovers from COVID, the damage that is done could be massive.”
Dissolving scar tissue is another area in which enzymes, particularly proteolytic enzymes, may be useful.
A Breakdown of the Top 3 Fibrinolytics
Fibrinolytic enzymes are ideal for targeted usage; as mentioned, if you intend to use them daily, be sure to alternate through the following types so you don’t develop a sensitivity or allergy to them. Also, remember that they need to be taken on an empty stomach, at least one hour before or two hours after meals containing protein.1. Lumbrokinase
This enzyme is about 300 times stronger than serrapeptase and nearly 30 times stronger than nattokinase, making it my top recommendation if you are using a fibrinolytic enzyme. Extracted from earthworms, lumbrokinase is a highly effective antithrombotic agent that reduces blood viscosity and platelet aggregation while also degrading fibrin, which is a key factor in clot formation.I recommend that everyone keep some high-quality lumbrokinase in their emergency kit. I recently had a significant bruise from a weight training injury. I took a high dose of lumbrokinase for a week and it cleared right up.
I also took lumbrokinase recently after being stung by three wasps on my forehead just before bed, which swelled to nearly the size of half a tennis ball. Wasp venom contains proteins that fibrinolytic enzymes can break down, so I took half a dozen and went to sleep.
2. Serrapeptase
Also known as serratiopeptidase, serrapeptase is produced in the gut of newborn Bombyx mori silkworms, allowing them to dissolve and escape from their cocoons.3. Nattokinase
Nattokinase has been shown to break down blood clots and reduce the risk of serious clotting by dissolving excess fibrin in your blood vessels, improving circulation, and decreasing blood viscosity.Sources and References
- 1 Britannica, Enzyme
- 2, 3 Front. Cardiovasc. Med., 22 August 2022, Intro
- 4 Int J Mol Sci. 2017 Mar; 18(3): 523
- 5, 32 Biol Pharm Bull. 1995 Oct;18(10):1387-91
- 6 Lab Anim Res December 2013; 29(4): 221-225
- 7, 27 Townsend Letter May 2018
- 8 Enzymatic Activity Comparison of Common Fibrinolytic Enzymes 2011
- 9 Lumbrokinase Reference List May 2018
- 10, 11 Front. Cardiovasc. Med., 22 August 2022
- 12, 13 Scientific Reports volume 5, Article number: 11601 (2015)
- 14 Lab Tests Online, D-dimer
- 15 Scientific Reports volume 5, Article number: 11601 (2015), Discussion
- 16 Lab Anim Res. 2013 Dec; 29(4): 221–225
- 17 Hum Exp Toxicol. 2013 Jul;32(7):721-35. doi: 10.1177/0960327112467040
- 18 Med. Hypotheses. 2017;106:1–5
- 19 Neurosci. Lett. 2016 Sep 6;630:247-253
- 20, 22, 34 J Thromb Haemost. 2020 May 11; doi: 10.1111/jth.14828
- 21 Diapharma, Tissue Plasminogen Activator
- 23 EBioMedicine November 3, 2020
- 24, 25 Reuters November 3, 2020
- 26 The Texan November 3, 2020
- 28 Trials volume 23, Article number: 285 (2022), Introduction
- 29 Respirology 2003 Sep;8(3):316-20
- 30 International Journal of Surgery, 2013 Apr;11(3):209-217
- 31 Scientific Reports 2015; 5: 11601
- 33 Scientific Reports. Article Number 6210. April 18, 2018